Show simple item record

dc.contributor.authorChung, Eunice S.en_US
dc.contributor.authorSabel, Michael S.en_US
dc.contributor.authorSondak, Vernon K.en_US
dc.date.accessioned2006-09-11T19:36:57Z
dc.date.available2006-09-11T19:36:57Z
dc.date.issued2004-04en_US
dc.identifier.citationChung, E. S.; Sabel, M. S.; Sondak, V. K.; (2004). "Current state of treatment for primary cutaneous melanoma." Clinical and Experimental Medicine 4(2): 65-77. <http://hdl.handle.net/2027.42/47975>en_US
dc.identifier.issn1591-9528en_US
dc.identifier.issn1591-8890en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/47975
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15672943&dopt=citationen_US
dc.description.abstractThe incidence of malignant melanoma has been rising steadily for the last 30 years. Through physician and patient education, surveillance of high-risk individuals, and biopsy of any suspicious lesions, more lesions are being diagnosed earlier, where there is a high cure rate. Unfortunately many patients will still present with thicker lesions or nodal involvement, which carries a significantly worse prognosis. Over the past decade, there have been several changes in the management of primary cutaneous melanoma. These have stemmed from novel surgical approaches, a new understanding of melanoma biology, and randomized clinical trials designed to improve outcome and decrease the morbidity of therapy. This article will review the clinical evidence behind the current treatment recommendations for primary cutaneous melanoma as well as some of the emerging data on innovative immunologic-approaches to melanoma treatment.en_US
dc.format.extent150974 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherSpringer-Verlag; Springer-VerlagItaliaen_US
dc.subject.otherMedicineen_US
dc.subject.otherVaccinesen_US
dc.subject.otherSentinel Lymph Node Biopsyen_US
dc.subject.otherMelanomaen_US
dc.subject.otherInterferonen_US
dc.titleCurrent state of treatment for primary cutaneous melanomaen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Surgical Oncology, University of Michigan Medical School, Ann Arbor, MI, 48109-0031, USA, ; 3304 Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI, 48109, USA,en_US
dc.contributor.affiliationumDivision of Surgical Oncology, University of Michigan Medical School, Ann Arbor, MI, 48109-0031, USA,en_US
dc.contributor.affiliationumDivision of Surgical Oncology, University of Michigan Medical School, Ann Arbor, MI, 48109-0031, USA,en_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid15672943en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/47975/1/10238_2004_Article_40.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/s10238-004-0040-5en_US
dc.identifier.sourceClinical and Experimental Medicineen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record